Investigating tumor-host response dynamics in preclinical immunotherapy experiments using a stepwise mathematical modeling strategy

Esfahani, 2020, A review of cancer immunotherapy: from the past, to the present, to the future, Curr. Oncol, 27, S87, 10.3747/co.27.5223 Waldman, 2020, A guide to cancer immunotherapy: from T cell basic science to clinical practice, Nat. Rev. Immunol, 20, 651, 10.1038/s41577-020-0306-5 Sharma, 2017, Primary, adaptive, and acquired resistance to cancer immunotherapy, Cell, 168, 707, 10.1016/j.cell.2017.01.017 Darvin, 2018, Immune checkpoint inhibitors: recent progress and potential biomarkers, Exp. Mol. Med., 50, 1, 10.1038/s12276-018-0191-1 Shieh, 2021, Response to immune checkpoint inhibitor treatment in advanced cervical cancer and biomarker study, Front. Med. (Lausanne), 8 Haslam, 2019, Estimation of the Percentage of US patients with cancer who are eligible for and respond to checkpoint inhibitor immunotherapy drugs, JAMA Netw Open, 2, 10.1001/jamanetworkopen.2019.2535 Nakamura, 2017, Targeting cancer-related inflammation in the era of immunotherapy, Immunol. Cell Biol., 95, 325, 10.1038/icb.2016.126 Wang, 2019, simulation of a clinical trial with anti-CTLA-4 and anti-PD-L1 immunotherapies in metastatic breast cancer using a systems pharmacology model, R Soc. Open Sci., 6, 10.1098/rsos.190366 Butner, 2020, Mathematical prediction of clinical outcomes in advanced cancer patients treated with checkpoint inhibitor immunotherapy, Sci. Adv., 6, eaay6298, 10.1126/sciadv.aay6298 Syed, 2023, Immune-checkpoint inhibitor therapy response evaluation using oncophysics-based mathematical models, Wiley Interdiscip Rev. Nanomed Nanobiotechnol, 15, e1855, 10.1002/wnan.1855 Reeves, 2022, (18)F-FMISO PET imaging identifies hypoxia and immunosuppressive tumor microenvironments and guides targeted Evofosfamide therapy in tumors refractory to PD-1 and CTLA-4 inhibition, Clin. Cancer Res, 28, 327, 10.1158/1078-0432.CCR-21-2394 Jain, 2005, Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy, Science, 307, 58, 10.1126/science.1104819 Harris, 2002, Hypoxia–a key regulatory factor in tumour growth, Nat. Rev. Cancer, 2, 38, 10.1038/nrc704 Vaupel, 2004, Tumor hypoxia and malignant progression, Methods Enzymol, 381, 335, 10.1016/S0076-6879(04)81023-1 Bannoud, N., et al., Hypoxia supports differentiation of terminally exhausted CD8 T cells. Front. Immunol, 2021. 12: p. 660944. Noman, 2019, Improving cancer immunotherapy by targeting the hypoxic tumor microenvironment: new opportunities and challenges, Cells, 8, 10.3390/cells8091083 Zheng, 2018, Increased vessel perfusion predicts the efficacy of immune checkpoint blockade, J. Clin. Invest, 128, 2104, 10.1172/JCI96582 Sorace, 2020, Imaging for response assessment in cancer clinical trials, Semin. Nucl. Med, 50, 488, 10.1053/j.semnuclmed.2020.05.001 Napier, 2022, Preclinical PET imaging of Granzyme B shows promotion of immunological response following combination paclitaxel and immune checkpoint inhibition in triple negative breast cancer, Pharmaceutics, 14, 10.3390/pharmaceutics14020440 Larimer, 2019, The effectiveness of checkpoint inhibitor combinations and administration timing can be measured by Granzyme B PET imaging, Clin. Cancer Res, 25, 1196, 10.1158/1078-0432.CCR-18-2407 Lim, 1993, An efficient radiosynthesis of [18F]fluoromisonidazole, Appl. Radiat. Isot, 44, 1085, 10.1016/0969-8043(93)90110-V Tang, 2005, Fully automated one-pot synthesis of [18F]fluoromisonidazole, Nucl. Med. Biol, 32, 553, 10.1016/j.nucmedbio.2005.03.010 Sorace, 2017, Quantitative [(18)F]FMISO PET Imaging Shows Reduction of Hypoxia Following Trastuzumab in a Murine Model of HER2+ Breast Cancer, Mol. Imaging Biol, 19, 130, 10.1007/s11307-016-0994-1 Hanahan, 2011, Hallmarks of cancer: the next generation, Cell, 144, 646, 10.1016/j.cell.2011.02.013 Folkman, 1971, Tumor Angiogenesis - Therapeutic Implications, New England J. Med., 285 Schaaf, 2018, Defining the role of the tumor vasculature in antitumor immunity and immunotherapy, Cell Death Dis, 9, 115, 10.1038/s41419-017-0061-0 Wei, 2018, Fundamental mechanisms of immune checkpoint blockade therapy, Cancer Discov, 8, 1069, 10.1158/2159-8290.CD-18-0367 Granier, 2017, Mechanisms of action and rationale for the use of checkpoint inhibitors in cancer, ESMO Open,, 2, 10.1136/esmoopen-2017-000213 Chow, 2014, Chemokines in cancer, Cancer Immunol. Res, 2, 1125, 10.1158/2326-6066.CIR-14-0160 Briukhovetska, 2021, Interleukins in cancer: from biology to therapy, Nat. Rev. Cancer, 21, 481, 10.1038/s41568-021-00363-z Wang, 2008, Tumor necrosis factor and cancer, buddies or foes?, Acta Pharmacol. Sin, 29, 1275, 10.1111/j.1745-7254.2008.00889.x Roland, 2009, Cytokine levels correlate with immune cell infiltration after anti-VEGF therapy in preclinical mouse models of breast cancer, PLoS ONE, 4, e7669, 10.1371/journal.pone.0007669 Chew, 2012, Immune microenvironment in tumor progression: characteristics and challenges for therapy, J. Oncol., 2012, 10.1155/2012/608406 McBride, 1986, Induction of tolerance to a murine fibrosarcoma in two zones of dosage–the involvement of suppressor cells, Br. J. Cancer, 53, 707, 10.1038/bjc.1986.122 Mahapatro, 2021, Cytokine-mediated crosstalk between immune cells and epithelial cells in the gut, Cells, 10, 10.3390/cells10010111 Salemme, 2021, The crosstalk between tumor cells and the immune microenvironment in breast cancer: implications for immunotherapy, Front. Oncol., 11, 10.3389/fonc.2021.610303 Jarrett, 2019, Experimentally-driven mathematical modeling to improve combination targeted and cytotoxic therapy for HER2+ breast cancer, Sci. Rep, 9, 12830, 10.1038/s41598-019-49073-5 Selby, 2013, Anti-CTLA-4 antibodies of IgG2a isotype enhance antitumor activity through reduction of intratumoral regulatory T cells, Cancer Immunol. Res, 1, 32, 10.1158/2326-6066.CIR-13-0013 Selby, 2016, Preclinical development of ipilimumab and nivolumab combination immunotherapy: mouse tumor models, in vitro functional studies, and cynomolgus macaque toxicology, PLoS ONE, 11, 10.1371/journal.pone.0161779 Strogatz, 2000 Jarrett, 2018, Mathematical modelling of trastuzumab-induced immune response in an in vivo murine model of HER2+ breast cancer, Math Med. Biol Bloom, 2020, Anti-HER2 induced myeloid cell alterations correspond with increasing vascular maturation in a murine model of HER2+ breast cancer, BMC Cancer, 20, 359, 10.1186/s12885-020-06868-4 Noman, 2015, Hypoxia: a key player in antitumor immune response. A review in the theme: cellular responses to Hypoxia, Am. J. Physiol. Cell Physiol, 309, C569, 10.1152/ajpcell.00207.2015 Lestini, 2016, Optimal design for informative protocols in xenograft tumor growth inhibition experiments in mice, AAPS J., 18, 1233, 10.1208/s12248-016-9924-z Cárdenas, 2022, Model-informed experimental design recommendations for distinguishing intrinsic and acquired targeted therapeutic resistance in head and neck cancer, NPJ Syst. Biol. Appl., 8, 32, 10.1038/s41540-022-00244-7 Bandara, 2009, Optimal experimental design for parameter estimation of a cell signaling model, PLoS Comput. Biol, 5, 10.1371/journal.pcbi.1000558 Jarrett, 2020, Optimal Control Theory for Personalized Therapeutic Regimens in Oncology: background, History, Challenges, and Opportunities, J. Clin. Med., 9 Lima, 2022, Optimizing combination therapy in a murine model of HER2+ breast cancer, Comput. Methods Appl. Mech. Eng, 402